Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Stamp out lung cancer.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020 Jan; 16(1):4289-4301.
View in:
PubMed
subject areas
Antineoplastic Agents
Biomarkers, Tumor
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms
Prognosis
Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-met
Tissue Distribution
authors with profiles
Ravi Salgia